Literature DB >> 22339726

Liposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in mice.

Chieko Murayama1, Akira T Kawaguchi, Kenji Ishikawa, Akemi Kamijo, Nobusuke Kato, Yukio Ohizumi, Sotaro Sadahiro, Munetaka Haida.   

Abstract

We hypothesize that liposome-encapsulated hemoglobin with high O₂ affinity (P₅₀0₂ = 12 mm Hg, h-LEH) may increase O₂ delivery to hypoxic tumors and enhance radiation therapy synergistically to suppress tumor growth. First, h-LEH (5, 10, and 20 mL/kg) was intravenously infused 30 min before radiation (20 Gy) of SCCVII tumor grown in C3H/HeN mice. Second, 10 mL/kg of h-LEH was administered 30, 60, 90, and 120 min prior to radiation to determine optimal timing. Tumor size was monitored thereafter to titrate tumor growth suppression. Third, additional mice with SCCVII tumor were infused with h-LEH or empty liposome (EL), and tumors were excised at various time points for immunohistochemical examination of h-LEH and hypoxia-inducible factor-1α (HIF-1α). h-LEH was most effective at 10 mL/kg in comparison to 5 or 20 mL/kg of h-LEH or EL. Tumor growth was most suppressed when the interval between h-LEH infusion and radiation was shortest, 30 min. As a result, 10 mL/kg of h-LEH infusion 30 min prior to radiation prolonged 5-fold tumor-growth time from 20.0 days (radiation and EL) to 26.5 days, P<0.01, synergy ratio 1.42. While human hemoglobin (h-LEH) was detected in tumors 0.5 to 24 h after administration, HIF-1α accumulation was sparse and became significantly reduced compared to controls 48 and 72 h after h-LEH infusion. h-LEH (10 mL/kg) was highly effective in enhancing radiation therapy synergistically under ambient respiration against tumor growth in mice. Decreased accumulation of HIF-1α in h-LEH-treated tumor may suggest targeted tumor oxygenation as a potential mechanism.
© 2012, Copyright the Authors. Artificial Organs © 2012, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22339726     DOI: 10.1111/j.1525-1594.2011.01418.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  7 in total

1.  Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy.

Authors:  Jinping Wang; Beilu Zhang; Jingyu Sun; Yuhao Wang; Hongjun Wang
Journal:  Adv Ther (Weinh)       Date:  2019-09-30

2.  Enhancement of radiotherapy efficacy by pleiotropic liposomes encapsulated paclitaxel and perfluorotributylamine.

Authors:  Xing Jiang; Baoli Zhang; Zaigang Zhou; Lingtong Meng; Zhiling Sun; Yun Xu; Qiuping Xu; Ahu Yuan; Lixia Yu; Hanqing Qian; Jinhui Wu; Yiqiao Hu; Baorui Liu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 3.  Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies - exemplified by polyunsaturated fatty acids and other ROS-modulating agents.

Authors:  Rui Xue Zhang; Franky Fuh-Ching Liu; Hoyin Lip; Junhong Liu; Qianrong Zhang; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2022-01-22       Impact factor: 5.671

4.  Liposome encapsulated perfluorohexane enhances radiotherapy in mice without additional oxygen supply.

Authors:  Linfeng Xu; Xuefeng Qiu; Yanting Zhang; Kai Cao; Xiaozhi Zhao; Jinhui Wu; Yiqiao Hu; Hongqian Guo
Journal:  J Transl Med       Date:  2016-09-20       Impact factor: 5.531

Review 5.  Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.

Authors:  Kaitlin Graham; Evan Unger
Journal:  Int J Nanomedicine       Date:  2018-10-04

6.  A Robust Oxygen Microbubble Radiosensitizer for Iodine-125 Brachytherapy.

Authors:  Sheng Peng; Ruyuan Song; Qingguang Lin; Yanling Zhang; Yuanzhong Yang; Ma Luo; Zhihui Zhong; Xiaonan Xu; Ligong Lu; Shuhuai Yao; Fujun Zhang
Journal:  Adv Sci (Weinh)       Date:  2021-02-10       Impact factor: 16.806

Review 7.  Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma.

Authors:  Hui Yan; Bo Zhai; Fang Yang; Zhenliang Chen; Qiang Zhou; Ana Cláudia Paiva-Santos; Ziqiao Yuan; Yang Zhou
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.